Clinical trial
Donepezil Hydrochloride (E2020) in Dementia Associated With Cerebrovascular…
NCT00165737 · Eisai Inc., Industry · Completed
Key facts
| NCT number | NCT00165737 |
|---|---|
| Title | Donepezil Hydrochloride (E2020) in Dementia Associated With Cerebrovascular Disease |
| Official title | A 24-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy, Safety and Tolerability of Donepezil Hydrochloride (E2020) in Patients With Dementia Associated With Cerebrovascular Disease |
| Lead sponsor | Eisai Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Dementia, Vascular |
| Intervention type | Drug |
| Interventions | Donepezil Hydrochloride |
| Enrollment | 974 |
| Start date | Mar 1, 2003 |
| Primary completion | Aug 1, 2005 |
| Completion | Jun 1, 2006 |
| First posted | Sep 14, 2005 |
| Last update posted | Apr 1, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: